Search details
1.
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Blood
; 139(13): 2024-2037, 2022 03 31.
Article
in English
| MEDLINE | ID: mdl-34936696
2.
Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
Circ Res
; 129(1): e21-e34, 2021 06 25.
Article
in English
| MEDLINE | ID: mdl-33934611
3.
Case 15-2024: A 73-Year-Old Woman with Worsening Rash.
N Engl J Med
; 390(19): 1803-1813, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38749037
4.
Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
Blood
; 134(17): 1430-1440, 2019 10 24.
Article
in English
| MEDLINE | ID: mdl-31383641
5.
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Blood
; 131(25): 2836-2845, 2018 06 21.
Article
in English
| MEDLINE | ID: mdl-29549175
6.
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Br J Haematol
; 185(4): 679-690, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30828801
7.
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
Blood
; 129(13): 1791-1801, 2017 Mar 30.
Article
in English
| MEDLINE | ID: mdl-28126925
8.
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Am J Hematol
; 94(6): 641-649, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30896890
9.
Prevalence of autoimmune diseases in cutaneous B-cell lymphoma: A retrospective cross sectional analysis.
J Am Acad Dermatol
; 90(1): 177-179, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37730019
10.
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.
J Cell Mol Med
; 22(8): 3887-3898, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29761849
11.
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Br J Haematol
; 176(6): 929-938, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28107546
12.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Blood
; 126(3): 354-62, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-26048911
13.
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Leuk Lymphoma
; : 1-10, 2024 Mar 22.
Article
in English
| MEDLINE | ID: mdl-38517235
14.
KLRG1 Cell Depletion As A Novel Therapeutic Strategy In Patients With Mature T-cell lymphoma Subtypes.
Clin Cancer Res
; 2024 Jan 22.
Article
in English
| MEDLINE | ID: mdl-38252421
15.
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Nat Cancer
; 4(10): 1508-1525, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37723306
16.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Sci Transl Med
; 15(714): eadi7244, 2023 09 20.
Article
in English
| MEDLINE | ID: mdl-37729434
17.
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.
Blood Adv
; 6(16): 4740-4762, 2022 08 23.
Article
in English
| MEDLINE | ID: mdl-35816645
18.
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Blood Adv
; 6(5): 1420-1431, 2022 03 08.
Article
in English
| MEDLINE | ID: mdl-35026839
19.
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
Blood Adv
; 7(14): 3760-3763, 2023 07 25.
Article
in English
| MEDLINE | ID: mdl-36790924
20.
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
Mol Cancer Ther
; 16(10): 2304-2314, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28729399